Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based ChemotherapyEvelyn Despierre, Antonio Jimeno|Targeted Oncology|2015Cited by 29